reports
- Jesper Ingildsen
ChemoMetec (Buy, TP: DKK540.00) - More than on track
The Q1 results were much stronger than expected, even after the increased full-year guidance in October, which now already looks conservative to us. In our view, this looks like a ‘beat and raise’ strategy, and we would not be surprised to see several guidance increases as new products increasingly contribute and end-markets continue to improve, which, considering the operating leverage, could drive significant positive consensus earnings revisions. We reiterate our BUY and have raised our targe...
ChemoMetec A S: 2 directors
Two Directors at ChemoMetec A S bought 9,175 shares at between 456.010DKK and 459.980DKK. The significance rating of the trade was 64/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...
Indberetning af ledende medarbejderes transaktioner
Indberetning af ledende medarbejderes transaktioner MEDDELELSE NR. 284 8. november 2024 Indberetning af ledende medarbejderes transaktioner ChemoMetec A/S har i henhold til artikel 19 i forordning (EU) nr. 596/2014 modtaget nedenstående indberetning om transaktioner i ChemoMetec A/S aktier udført af personer med ledelsesansvar og/eller personer, der er nært knyttet til dem. Se indberetning af næstformand for bestyrelsen Martin Glensbjergs transaktioner i vedhæftede pdf-dokument. Yderligere oplysninger kan fås ved henvendelse til: Kim Nicolajsen, CFO Telefon: (+45) 48 13 10 20 ...
Notification of managers’ transactions
Notification of managers’ transactions ANNOUNCEMENT NO. 284 8 November 2024 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them. See the transactions of the Vice Chair of ChemoMetec’s Board of Directors Martin Glensbjerg in the attached PDF document. For further information, please contact: Kim Nicolajsen, CFOTelephone (+45) ...
Indberetning af ledende medarbejderes transaktioner
Indberetning af ledende medarbejderes transaktioner MEDDELELSE NR. 283 8. november 2024 Indberetning af ledende medarbejderes transaktioner ChemoMetec A/S har i henhold til artikel 19 i forordning (EU) nr. 596/2014 modtaget nedenstående indberetning om transaktioner i ChemoMetec A/S aktier udført af personer med ledelsesansvar og/eller personer, der er nært knyttet til dem. Se indberetning af administrerende direktør Martin Helbo Behrens’ transaktioner i vedhæftede pdf-dokument. Yderligere oplysninger kan fås ved henvendelse til: Kim Nicolajsen, CFO Telefon: (+45) 48 13 10...
Notification of managers’ transactions
Notification of managers’ transactions ANNOUNCEMENT NO. 283 8 November 2024 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them. See the transactions of the CEO Martin Helbo Behrens in the attached PDF document. For further information, please contact: Kim Nicolajsen, CFOTelephone (+45) 48 13 10 20 About ChemoM...
Vækst i omsætning og driftsresultat
Vækst i omsætning og driftsresultat Periodemeddelelse for 1. kvartal 2024/25 (1. juli - 30. september 2024) Vækst i omsætning og driftsresultat Omsætningen steg i 1. kvartal med 27% til DKK 115,6 mio. mod DKK 91,1 mio. i samme periode sidste år. Udviklingen afspejler en fremgang i salget af både instrumenter, forbrugsvarer og services. Resultatet af primær drift (EBITDA) steg i 1. kvartal med 50% til DKK 62,1 mio. drevet af den stigende omsætning. EBITDA-marginen blev i 1. kvartal på 54%. 2024/251. kvartal 2023/241. kvartal Ændring, %Omsætning, DKK mio. 115,6 91,1 +27EBITDA, DKK mio. 6...
Growth in revenue and operating profit
Growth in revenue and operating profit Trading statement for Q1 2024/25 (1 July - 30 September 2024) Growth in revenue and operating profit Revenue was up 27% in the first quarter of 2024/25 to DKK 115.6 million from DKK 91.1 million in the year-earlier period. The performance reflects growing sales of both instruments, consumables and services. Operating profit (EBITDA) was up 50% in the first quarter to DKK 62.1 million, driven by the revenue growth. The EBITDA margin was 54% for the first quarter. 2024/25Q1 2023/24Q1 Change, %Revenue, DKKm 115.6 91.1 +27EBITDA, DKKm 62.1 41.5 +50E...
Endelig overtagelse af Ovizio Imaging Systems SA
Endelig overtagelse af Ovizio Imaging Systems SA MEDDELELSE NR. 281 22. oktober 2024 Endelig overtagelse af Ovizio Imaging Systems SA Samtlige kapitalejere har nu accepteret ChemoMetecs købstilbud, hvorefter der i dag er gennemført closing og dermed endelig overtagelse af 100% af kapitalandelene i den belgiske virksomhed Ovizio Imaging Systems SA for den tidligere udmeldte købspris på EUR 2.830.000. Yderligere oplysninger Martin Helbo Behrens, CEOTelefon: (+45) 48 13 10 20 Kim Nicolajsen, CFOTelefon (+45) 48 13 10 20 Om Ovizio Ovizio har udviklet en holografisk base...
Closing of acquisition of Ovizio Imaging Systems SA
Closing of acquisition of Ovizio Imaging Systems SA ANNOUNCEMENT NO. 281 22 October 2024 Closing of acquisition of Ovizio Imaging Systems SA All capital owners have now accepted ChemoMetec's takeover offer, and closing has been completed today and thus the final acquisition of 100% of the capital in the Belgian company Ovizio Imaging Systems SA for the previously announced purchase price of EUR 2,830,000. Additional information Martin Helbo Behrens, CEOTel.: (+45) 48 13 10 20 Kim Nicolajsen, CFOTel.: (+45) 48 13 10 20 About Ovizio Ovizio has developed a cell count...
Acquisition of Ovizio Imaging Systems SA
Acquisition of Ovizio Imaging Systems SA ANNOUNCEMENT NO. 280 16 October 2024 Acquisition of Ovizio Imaging Systems SA On the basis of the completed due diligence, ChemoMetec today submitted a binding tender offer for the acquisition of 100% of the shares of Belgian company Ovizio Imaging Systems SA (’Ovizio’). The acquisition price is EUR 2,830,000. The tender offer has already been accepted by shareholders owning more than two thirds of Ovizio, and ChemoMetec is currently in the process of obtaining acceptance from the remaining shareholders, who are under a legal obligation to ...
Opjustering af omsætning og driftsresultat
Opjustering af omsætning og driftsresultat MEDDELELSE NR. 279 16. oktober 2024 Opjustering af omsætning og driftsresultat ChemoMetec har i første kvartal af regnskabsåret 2024/25 fortsat sin positive udvikling, hvor salget og ordretilgangen har udviklet sig bedre end forventet. På baggrund heraf forventes der nu en omsætning i regnskabsåret 2024/25 på DKK 445-460 mio. mod senest udmeldt DKK 435-450 mio., og EBITDA forventes at ligge i intervallet DKK 222-230 mio. mod senest udmeldt DKK 216-223 mio. ChemoMetecs periodemeddelelse for første kvartal 2024/25 forventes offentliggjort tor...
Upgrade of revenue and operating profit guidance
Upgrade of revenue and operating profit guidance ANNOUNCEMENT NO. 279 16 October 2024 Upgrade of revenue and operating profit guidance ChemoMetec sustained its positive performance in the first quarter of 2024/25 with better-than-expected sales and order intake. Based on this, the Company now expects revenue for the 2024/25 financial year in the DKK 445-460 million range, up from DKK 435-450 million in the most recent guidance, and EBITDA in the DKK 222-230 million range, up from DKK 216-223 million previously. ChemoMetec’s interim report for Q1 2024/25 is scheduled to be released o...
ChemoMetecs mulige overtagelse af Ovizio Imaging Systems SA
ChemoMetecs mulige overtagelse af Ovizio Imaging Systems SA MEDDELELSE NR. 278 11. oktober 2024 ChemoMetecs mulige overtagelse af Ovizio Imaging Systems SA Som omtalt i selskabsmeddelelse nr. 276 har ChemoMetec afgivet et indikativt købstilbud på den belgiske virksomhed Ovizio Imaging Systems SA. Som tillige oplyst i meddelelsen, forventede ChemoMetec at gennemføre due diligence inden for tre uger og med overvejende sandsynlighed at gennemføre købet, hvis resultatet heraf var positivt. Den omtalte due diligence og forhandlingerne om endelig købsaftale pågår fortsat, og såfr...
ChemoMetec’s potential acquisition of Ovizio Imaging Systems SA
ChemoMetec’s potential acquisition of Ovizio Imaging Systems SA ANNOUNCEMENT NO. 278 11 October 2024 ChemoMetec’s potential acquisition of Ovizio Imaging Systems SA As mentioned in company announcement no. 276, ChemoMetec has made an indicative purchase offer for the Belgian company Ovizio Imaging Systems SA. As also stated in the announcement, ChemoMetec expected to complete the due diligence within three weeks and most likely to complete the acquisition, if the outcome was positive. The mentioned due diligence and negotiations on the final share purchase agreement are still ongoing...
Forløb af ordinær generalforsamling
Forløb af ordinær generalforsamling MEDDELELSE NR. 277 10. oktober 2024 Forløb af ordinær generalforsamling Den ordinære generalforsamling i ChemoMetec A/S blev afholdt den 10. oktober 2024 kl. 17.30 hos Nordsjællands KonferenceCenter. På generalforsamlingen blev bestyrelsens beretning om selskabets virksomhed i det forløbne år fremlagt, årsrapporten for 2023/24 blev godkendt, og bestyrelsen samt direktionen blev meddelt decharge. Generalforsamlingen godkendte det af bestyrelsen fremsatte forslag om udlodning af udbytte på DKK 4 pr. aktie a nominelt DKK 1. Niels Thestru...
Procedure of the Annual General Meeting
Procedure of the Annual General Meeting ANNOUNCEMENT NO. 277 10 October 2024 Procedure of the Annual General Meeting The Annual General Meeting of ChemoMetec A/S was held on 10 October 2024 at 5.30 p.m. at Nordsjællands KonferenceCenter. At the Annual General Meeting, the Board of Directors' report on the company's activities during the past year was presented, the annual report for 2023/24 was approved, and the Board of Directors and the Executive Board were granted discharge. The Annual General Meeting approved the proposal of the Board of Directors to distribute a divide...
ChemoMetec afgiver købstilbud på Ovizio Imaging Systems SA
ChemoMetec afgiver købstilbud på Ovizio Imaging Systems SA MEDDELELSE NR. 276 20. september 2024 Købstilbud afgivet på virksomheden Ovizio Imaging Systems SA ChemoMetec har afgivet et indikativt købstilbud på den belgiske virksomhed Ovizio Imaging Systems (’Ovizio’), som er blevet accepteret af virksomhedens ejerkreds. ChemoMetec har nu tre uger til at gennemføre due diligence, og hvis resultatet af denne er positivt, vil ChemoMetec med overvejende sandsynlighed gennemføre købet. Ovizio har udviklet en holografisk baseret celletæller, der primært anvendes inden for bioprocessin...
ChemoMetec makes offer to buy Ovizio Imaging Systems SA
ChemoMetec makes offer to buy Ovizio Imaging Systems SA ANNOUNCEMENT NO. 276 20 September 2024 ChemoMetec makes offer to buy Ovizio Imaging Systems SA ChemoMetec has submitted an indicative offer to buy Belgian company Ovizio Imaging Systems (‘Ovizio’), which has been accepted by the company’s group of owners. ChemoMetec now has three weeks to carry out a due diligence, and if the outcome of this is positive, ChemoMetec will most likely proceed with the acquisition. Ovizio has developed a cell counter based on holographic microscopy. The instrument is primarily used in bio...
Indkaldelse til ordinær generalforsamling 2024
Indkaldelse til ordinær generalforsamling 2024 MEDDELELSE NR. 275 18. september 2024 Indkaldelse til ordinær generalforsamling Vedlagt offentliggøres selskabets indkaldelse til ordinær generalforsamling, som afholdes torsdag den 10. oktober 2024 kl. 17.30. Generalforsamlingen afholdes hos Nordsjællands KonferenceCenter, Gydevang 39-41, 3450 Allerød. Yderligere oplysninger Kim Nicolajsen, CFOTelefon: (+45) 48 13 10 20 Om ChemoMetec A/S ChemoMetec udvikler, producerer og markedsfører instrumenter til cell...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.